Literature DB >> 27561870

The Effect of Re-randomization in a Smoking Cessation Trial.

Eunhee Park1, Seung Hee Choi2, Sonia A Duffy3.   

Abstract

OBJECTIVES: The purpose of this sub-study was to determine whether operating engineers (heavy equipment operators) who failed to quit smoking in a randomized controlled trial would benefit from re-exposure to the interventions one year later.
METHODS: Operating Engineers attending workplace safety training groups during the winters of 2010 to 2012 were randomized by training group to either to the Tobacco Tactics Web-based intervention or the 1-800-QUIT-NOW telephone line. Of the 145 original participants, 41 reappeared in training groups one year later and were re-randomized with their group. Seven-day point prevalence quit rates at 30-days and 6-months post-intervention were analyzed using the chi-square test and Fisher's exact test.
RESULTS: At 30-day follow-up, an additional 9.8% (4/41) of repeaters had quit smoking. At 6-month follow-up, 12.2% (5/41) of repeaters had quit smoking. At 30-day follow-up, increased quitting was more common among those re-randomized to the intervention group than among those who received the control treatment, although this was not statistically significant and was no longer true at 6-month follow-up.
CONCLUSIONS: Because many smokers make multiple attempts to quit smoking, re-enrollment of participants in smoking cessation trials may produce additional quitters.

Entities:  

Mesh:

Year:  2016        PMID: 27561870      PMCID: PMC6764760          DOI: 10.5993/AJHB.40.5.14

Source DB:  PubMed          Journal:  Am J Health Behav        ISSN: 1087-3244


  35 in total

1.  Demographic differences in patterns in the incidence of smoking cessation: United States 1950-1990.

Authors:  Elizabeth A Gilpin; John P Pierce
Journal:  Ann Epidemiol       Date:  2002-04       Impact factor: 3.797

2.  Respiratory symptoms and lung function in workers in heavy and highway construction: a cross-sectional study.

Authors:  L C Oliver; H Miracle-McMahill; A B Littman; J M Oakes; R R Gaita
Journal:  Am J Ind Med       Date:  2001-07       Impact factor: 2.214

3.  Working class matters: socioeconomic disadvantage, race/ethnicity, gender, and smoking in NHIS 2000.

Authors:  Elizabeth M Barbeau; Nancy Krieger; Mah-Jabeen Soobader
Journal:  Am J Public Health       Date:  2004-02       Impact factor: 9.308

Review 4.  Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions.

Authors:  David Evans
Journal:  J Clin Nurs       Date:  2003-01       Impact factor: 3.036

5.  BCG in the treatment of acute lymphocytic leukemia.

Authors:  R M Heyn; P Joo; M Karon; M Nesbit; N Shore; N Breslow; J Weiner; A Reed; D Hammond
Journal:  Blood       Date:  1975-09       Impact factor: 22.113

6.  Measures of abstinence in clinical trials: issues and recommendations.

Authors:  John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan
Journal:  Nicotine Tob Res       Date:  2003-02       Impact factor: 4.244

7.  Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Authors:  Douglas Altman; Guillermo Carroli; Lelia Duley; Barbara Farrell; Jack Moodley; James Neilson; David Smith
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

8.  Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.

Authors:  Ferenc Martenyi; Eileen B Brown; Harry Zhang; Stephanie C Koke; Apurva Prakash
Journal:  Br J Psychiatry       Date:  2002-10       Impact factor: 9.319

9.  Use of re-randomized data in meta-analysis.

Authors:  Iztok Hozo; Benjamin Djulbegovic; Otavio Clark; Gary H Lyman
Journal:  BMC Med Res Methodol       Date:  2005-05-10       Impact factor: 4.615

10.  Testing the performance of the ENRICHD Social Support Instrument in cardiac patients.

Authors:  Joseph Vaglio; Mark Conard; Walker S Poston; James O'Keefe; C Keith Haddock; John House; John A Spertus
Journal:  Health Qual Life Outcomes       Date:  2004-05-13       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.